Atom Bioscience
Developing 1.1 category innovative drugs with global commercial value and global competitiveness for the treatment of metabolic diseases and tumors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $83.0m | Series D | |
| Total Funding | 000k | ||
Related Content
Atom Bioscience is a biotech startup focused on the development of innovative treatments for chronic gout, a type of inflammatory arthritis. The company operates in the pharmaceutical market, specifically in the area of rheumatology. Their primary product is a new investigational drug, ABP-671, which has shown promising results in Phase 2a clinical trials. The drug works by reducing uric acid levels in the body, a key factor in the development of gout.
The company's target clients are individuals suffering from chronic gout, a condition that is often misunderstood and stigmatized. Atom Bioscience aims to change the perception of gout, emphasizing that it is more related to genetics than lifestyle choices.
The business model of Atom Bioscience is based on the research, development, and commercialization of pharmaceutical products. The company generates revenue through the sale of its drugs once they have been approved by regulatory bodies and are available on the market.
In summary, Atom Bioscience is a promising biotech startup with a focus on developing effective treatments for chronic gout. Their innovative approach and positive clinical trial results position them well in the pharmaceutical market.
Keywords: Atom Bioscience, biotech startup, chronic gout, pharmaceutical market, rheumatology, investigational drug, ABP-671, uric acid reduction, genetics, drug commercialization.